To investigate calcium metabolism as a therapeutic target in multiple sclerosis (MS)

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00024950
• Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• In the group of patients without CCB therapy, no CCB therapy for at least 3 months
• In the cohort of patients with CCB therapy, no CCB therapy for at least 3 months
• Patients who have given written informed consent based on GCP guidelines

Exclusion Criteria

• Pregnancy
• Known autoimmune disease
• Acute/chronic infection
• Active Malignancy
• Chronic kidney disease > CKD stage 4
• Hypo-/Hypercalcemia
• Intake of calcium, vitamin D and its derivates
• Calcineurin-inhibitor treatment
• Therapy with calcimimetica
• Hyperparathyreoidism
• Patients who have not given written informed consent based on GCP guidelines

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate the role of calcium on the activation and differentiation of peripheral blood mononuclear cells (T cells, B cells and monocytes) in patients with hypertension, which received a calcium antagonist therapy, as compared to hypertensive patients without a calcium antagonist treatment.

Secondary Outcome Measures

Name	Time	Method
ot applicable